Serum IgG reactivities of patients with IPAH, patients with SSc with or without PAH, and healthy individuals with endothelial and HEp-2 cell antigens
| Patient groups/antigen sources | HUVEC | HMVEC-d | HMVEC-l | HEp-2 |
|---|---|---|---|---|
| IPAH, idiopathic pulmonary arterial hypertension; SSc, systemic sclerosis; HUVEC, human umbilical vein endothelial cells; HMVEC-d, human microvascular dermal endothelial cells; HMVEC-l, human microvascular lung endothelial cells; kDa, kiloDalton. | ||||
| Healthy individuals | ||||
| No of reactivity peaks | 7–9 | 9–12 | 9–12 | 7–9 |
| Main reactivity(ies) (no of individuals) | 36 kDa (51/65) | 45 kDa (39/65) | 28 kDa (26/65) | |
| 58 kDa (33/65) | 40 kDa (52/65) | 27 kDa (12/65) | ||
| 63 kDa (33/65) | 55 kDa (49/65) | 31 kDa (41/65) | ||
| 63 kDa (24/65) | 45 kDa (40/65) | |||
| 77 kDa (32/65) | ||||
| IPAH | ||||
| No of reactivity peaks | 5–7 | 8–10 | 8–10 | 7–9 |
| Main reactivities (no of patients) | 36 kDa (34/35) | 28 kDa (23/35) | 28 kDa (20/35) | 27 kDa (24/35) |
| 60 kDa (17/35) | 45 kDa (35/35) | 40 kDa (32/35) | 31 kDa (33/35) | |
| 58 kDa (32/35) | 53 kDa (35/35) | 45 kDa (20/35) | ||
| 63 kDa (29/35) | 68 kDa (16/35) | |||
| 68 kDa (17/35) | ||||
| SSc with PAH | ||||
| No of reactivity peaks | 8–10 | 8–10 | 8–10 | 6–8 |
| Main reactivity(ies) (no of patients) | 36 kDa (10/10) | 28 kDa (9/10) | 28 kDa (8/10) | 31 kDa (9/10) |
| 45 kDa (9/10) | 44 kDa (8/10) | 36 kDa (9/10) | ||
| 53 kDa (5/10) | 53 kDa (7/10) | 45 kDa (8/10) | ||
| 57 kDa (10/10) | 57 kDa (7/10) | 58 kDa (10/10) | ||
| 63 kDa (7/10) | 75 kDa (510) | 75 kDa (4/10) | ||
| 67 kDa (10/10) | 85 kDa (6/10) | |||
| 75 kDa (8/10) | ||||
| 85 kDa (6/10 | ||||
| Limited cutaneous SSc without PAH | ||||
| No of reactivity peaks | 6–8 | 4–6 | 8–12 | 8–10 |
| Main reactivities (no of patients) | 36 kDa (9/10) | 45 kDa (6/10) | 40 kDa (8/10) | 31 kDa (7/10) |
| 80 kDa (6/10) | 75 kDa (10/10) | 55 kDa (10/10) | 45 kDa (8/10) | |
| 85 kDa (810) | 70 kDa (7/10) | 75 kDa (8/10) | ||
| 75 kDa (8/10) | 85 kDa (5/10) | |||
| 85 kDa (9/10) | ||||
| 165 kDa (7/10) | ||||
| Diffuse SSc without PAH | ||||
| No of reactivity peaks | 6–8 | 7–9 | 10–12 | 6–9 |
| Main reactivity(ies) (no of patients) | 36 kDa (10/10) | 45 kDa (8/10) | 43 kDa (7/10) | 31 kDa (8/20) |
| 50 kDa (4/10) | 45 kDa (5/10) | 45 kDa (7/10) | ||
| 75 kDa (6/10) | 55 kDa (7/10) | 100 kDa (6/10) | ||
| 100 kDa (6/10) | 70 kDa (7/10) | |||
| 100 kDa (6/10) | ||||